Subscribe to RSS

DOI: 10.1055/s-0045-1801889
Complications of Percutaneous Irreversible Electroporation for Pancreatic Cancer: A Systematic Review
Funding None.

Abstract
Purpose The aim of the study was to systematically review the percutaneous irreversible electroporation (IRE) complications for pancreatic ductal adenocarcinoma (PDAC).
Methods This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers conducted a detailed search in PubMed and EMBASE databases from inception till May 2024. The studies reporting the complications of percutaneous IRE in PDAC using standard scales were included. The primary outcome of interest was the complication rate (including total number of complications and major and minor complications) associated with the percutaneous IRE. IRE-related mortality was also recorded.
Results Of the 2,324 studies, 14 (9 prospective and 3 retrospective) met the inclusion criteria. Of the 748 complications, 114 were major complications (15.2%) and 634 were minor complications (84.7%). The most common complications were abdominal pain (n = 137), diarrhea (n = 57), and nausea and/or vomiting (n = 45). Pancreatitis (n = 57), vascular thrombosis (n = 21), bleeding (n = 21), and biliary complications (n = 26), including bile leaks, cholangitis, and strictures, were other common complications. The overall IRE mortality was 4/584 (0.68%). IRE-related fatal complications included duodenal perforation (n = 2), hepatic artery and superior mesenteric artery thrombosis (n = 1), and purulent peritonitis (n = 1).
Conclusion Although complications are common after IRE for PDAC, most are minor complications. Major complications include bleeding and pancreaticobiliary complications.
Ethics Approval
As per the institute ethics committee, ethical approval is not required for systematic review and meta-analysis.
Availability of Data and Materials
All data associated with the manuscript have been presented in the paper.
Authors' Contributions
H.B., M.G., M.M. screened the studies, extracted data, performed quality assessment, and wrote the initial draft. V.S. and P.G. wrote the initial draft and critically revised the manuscript.
Publication History
Article published online:
03 February 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67 (01) 7-30
- 2 American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011
- 3 Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16 (07) 1727-1733
- 4 Huguet F, André T, Hammel P. et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25 (03) 326-331
- 5 Chauffert B, Mornex F, Bonnetain F. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19 (09) 1592-1599
- 6 Loehrer Sr PJ, Feng Y, Cardenes H. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29 (31) 4105-4112
- 7 Jones RP, Psarelli EE, Jackson R. et al; European Study Group for Pancreatic Cancer. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg 2019; 154 (11) 1038-1048
- 8 Hadjicostas P, Malakounides N, Varianos C, Kitiris E, Lerni F, Symeonides P. Radiofrequency ablation in pancreatic cancer. HPB (Oxford) 2006; 8 (01) 61-64
- 9 D'Onofrio M, Barbi E, Girelli R. et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 2010; 16 (28) 3478-3483
- 10 Lygidakis NJ, Sharma SK, Papastratis P. et al. Microwave ablation in locally advanced pancreatic carcinoma: a new look. Hepatogastroenterology 2007; 54 (77) 1305-1310
- 11 Thanos L, Poulou LS, Mailli L, Pomoni M, Kelekis DA. Image-guided radiofrequency ablation of a pancreatic tumor with a new triple spiral-shaped electrode. Cardiovasc Intervent Radiol 2010; 33 (01) 215-218
- 12 Wu Y, Tang Z, Fang H. et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol 2006; 94 (05) 392-395
- 13 Li J, Chen X, Yang H. et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J 2011; 87 (1024) 89-95
- 14 Pezzilli R, Serra C, Ricci C. et al. Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas 2011; 40 (01) 163-165
- 15 Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011; 13 (03) 168-173
- 16 Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally advanced pancreatic cancer: a review of local ablative therapies. Cancers (Basel) 2018; 10 (01) E16
- 17 Kalra N, Gupta P, Gorsi U. et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience. Cardiovasc Intervent Radiol 2019; 42 (04) 584-590
- 18 Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007; 6 (04) 307-312
- 19 Au JT, Wong J, Mittra A. et al. Irreversible electroporation is a surgical ablation technique that enhances gene transfer. Surgery 2011; 150 (03) 474-479
- 20 José A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett 2012; 317 (01) 16-23
- 21 Ruarus AH, Vroomen LGPH, Geboers B. et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 2020; 294 (01) 212-220
- 22 Pan Q, Hu C, Fan Y, Wang Y, Li R, Hu X. Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer. JBUON 2020; 25 (03) 1643-1649
- 23 Månsson C, Nilsson A, Nygren P, Karlson BM. Ultrasound-guided percutaneous irreversible electroporation for treatment of locally recurrent pancreatic cancer after surgical resection. Anticancer Res 2020; 40 (05) 2771-2775
- 24 Månsson C, Brahmstaedt R, Nygren P, Nilsson A, Urdzik J, Karlson BM. Percutaneous irreversible electroporation as first-line treatment of locally advanced pancreatic cancer. Anticancer Res 2019; 39 (05) 2509-2512
- 25
Page MJ,
McKenzie JE,
Bossuyt PM.
et al.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ 2021; 372 (71) n71
MissingFormLabel
- 26 National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. NIH publication # 09–7473. Bethesda, MA: NIH; 2010
- 27 Clavien PA, Barkun J, de Oliveira ML. et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250 (02) 187-196
- 28 Narayanan G, Hosein PJ, Arora G. et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012; 23 (12) 1613-1621
- 29 Scheffer HJ, Vroomen LG, de Jong MC. et al. Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology 2017; 282 (02) 585-597
- 30 Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson BM. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol 2016; 42 (09) 1401-1406
- 31 Flak RV, Stender MT, Jensen TM. et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation: a Danish single center study of safety and feasibility. Scand J Gastroenterol 2019; 54 (02) 252-258
- 32 Narayanan G, Hosein PJ, Beulaygue IC. et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 2017; 28 (03) 342-348
- 33 Belfiore G, Belfiore MP, Reginelli A. et al. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer. Med Oncol 2017; 34 (03) 38
- 34 Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018; 9 (02) 275-281
- 35 Liu S, Qin Z, Xu J. et al. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. OncoTargets Ther 2019; 12: 1341-1350
- 36 Ma Y, Xing Y, Li H. et al. Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer. Front Immunol 2023; 14: 1193040
- 37 Tasu JP, Herpe G, Damion J. et al. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. Eur Radiol 2024; 34 (10) 6885-6895
- 38 Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma 2017; 4: 49-58
- 39 Sutter O, Calvo J, N'Kontchou G. et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology 2017; 284 (03) 877-886
- 40 Tempero MA, Malafa MP, Al-Hawary M. et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15 (08) 1028-1061
- 41 Casadei R, Ricci C, Pezzilli R. et al. A prospective study on radiofrequency ablation locally advanced pancreatic cancer. Hepatobiliary Pancreat Dis Int 2010; 9 (03) 306-311
- 42 Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97 (02) 220-225
- 43 Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 2011; 104 (01) 22-28
- 44 Martin II RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 2012; 215 (03) 361-369
- 45 Paiella S, Butturini G, Frigerio I. et al. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg 2015; 32 (02) 90-97
- 46 Martin II RC, Kwon D, Chalikonda S. et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015; 262 (03) 486-494 , discussion 492–494
- 47 Narayanan G, Daye D, Wilson NM, Noman R, Mahendra AM, Doshi MH. Ablation in pancreatic cancer: past, present and future. Cancers (Basel) 2021; 13 (11) 2511
- 48 Vogl TJ, Panahi B, Albrecht MH. et al. Microwave ablation of pancreatic tumors. Minim Invasive Ther Allied Technol 2018; 27 (01) 33-40
- 49 Varshney S, Sewkani A, Sharma S. et al. Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 2006; 7 (01) 74-78
- 50 Maiettini D, Mauri G, Varano G. et al. Pancreatic ablation: minimally invasive treatment options. Int J Hyperthermia 2019; 36 (02) 53-58
- 51 Xu KC, Niu LZ, Hu YZ. et al. A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol 2008; 14 (10) 1603-1611
- 52 Niu LZ, Li HB, Wen WF. et al. Feasibility and safety of percutaneous cryoablation for locally advanced pancreatic cancer. Zhonghua Yixianbing Zazhi 2011; 11: 1-4
- 53 Song ZG, Hao JH, Gao S, Gao CT, Tang Y, Liu JC. The outcome of cryoablation in treating advanced pancreatic cancer: a comparison with palliative bypass surgery alone. J Dig Dis 2014; 15 (10) 561-569
- 54 Niu L, He L, Zhou L. et al. Percutaneous ultrasonography and computed tomography guided pancreatic cryoablation: feasibility and safety assessment. Cryobiology 2012; 65 (03) 301-307
- 55 Scheffer HJ, Nielsen K, de Jong MC. et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014; 25 (07) 997-1011 , quiz 1011
- 56 Gupta P, Maralakunte M, Sagar S. et al. Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis. Eur Radiol 2021; 31 (09) 6511-6521